Literature DB >> 3662794

Thin malignant melanomas and recurrence potential.

H M Shaw1, W H McCarthy, S W McCarthy, G W Milton.   

Abstract

Of 846 patients with stage I malignant melanoma that was less than 0.76-mm thick who were followed up for two to 31 years, 61 (7.2%) developed a recurrence. For those patients who did not initially undergo an elective lymph node dissection, the majority of first recurrences were at regional lymph nodes. Attempts have been made to identify those patients at risk of relapsing. Axial lesions, particularly those on the scalp, had the highest recurrence rate, with 15% of all thin scalp lesions recurring compared with only 4% of all thin extremity lesions. Three histological features proved to be useful prognostic indicators when analyzed by single-factor analysis. Evidence of ulceration in the primary lesion increased the recurrence rate from 6.7% to 26.1%. While only 4.3% of lesions displaying low mitotic activity recurred, this rate rose to 23.8% for those lesions of a high mitotic grade. Only 5% of Clark's level II lesions recurred, compared with about 12% of lesions at either level III or IV. Evidence of regression in thin lesions had no deleterious effect on prognosis. This study defines a small subset of patients who may benefit from elective lymph node dissection.

Entities:  

Mesh:

Year:  1987        PMID: 3662794     DOI: 10.1001/archsurg.1987.01400220057011

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  7 in total

Review 1.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

2.  Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading.

Authors:  P Kaudewitz; O Braun-Falco; M Ernst; M Landthaler; W Stolz; J Gerdes
Journal:  Am J Pathol       Date:  1989-05       Impact factor: 4.307

3.  The melanocyte differentiation program predisposes to metastasis after neoplastic transformation.

Authors:  Piyush B Gupta; Charlotte Kuperwasser; Jean-Philippe Brunet; Sridhar Ramaswamy; Wen-Lin Kuo; Joe W Gray; Stephen P Naber; Robert A Weinberg
Journal:  Nat Genet       Date:  2005-09-04       Impact factor: 38.330

4.  Melanoma recurrence after excision: is a wide margin justified?

Authors:  H M Shaw; W H McCarthy
Journal:  Ann Surg       Date:  1994-01       Impact factor: 12.969

5.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

6.  Lethal "thin" malignant melanoma. Identifying patients at risk.

Authors:  C L Slingluff; R T Vollmer; D S Reintgen; H F Seigler
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

7.  Morphometric, DNA and PCNA in thin malignant melanomas.

Authors:  V Björnhagen; E Månsson-Brahme; J Lindholm; A Mattsson; G Auer
Journal:  Med Oncol Tumor Pharmacother       Date:  1993
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.